Welcome to the tag category page for Assessment of kidney function!
Farxiga is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes, reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and known cardiovascular disease or multiple cardiovascular risk factors, and treat chronic kidney disease and heart failure. Farxiga is an oral diabetes medicine that helps control blood sugar levels by helping the kidneys get rid of glucose. It belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors. Common side effects include hypoglycaemia, urinary tract infections, genital infections, and volume depletion. In clinical studies, people taking Farxiga lost up to about 7 pounds (3 kilograms) over 24 weeks of treatment. Farxiga is also known as dapagliflozin and Forxiga.
EGFR (estimated glomerular filtration rate) is a measure of how well the kidneys are working in filtering waste from the blood. The normal eGFR for adults is usually more than 90, but it declines with age even in people without kidney disease. A very low eGFR may indicate kidney failure. An eGFR test is used to evaluate kidney function, clinically. eGFR is an estimated number based on a blood test and age, sex, body type, and race. For patients younger than 40 years, CKD is defined by eGFR below 75 mL/min/1.73m2, for patients with ages between 40 and 65 years, CKD is defined by 60 mL/min/1.73m2. It is essential to know the cause of kidney disease and check the kidney function to plan treatment in case an eGFR falls below 60 for three months or more.
